EAU 2014 Articles

STOCKHOLM, SWEDEN (UroToday.com) - In this large multi-center study, authors retrospectively evaluated the efficacy outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) plus prednisone (P) vs P alone in pivotal studies COU-AA-301 (post-docetaxel) and COU-AA-302 (chemo-naïve), by Gleason score (≥ 8 or < 8), at initial diagnosis.

STOCKHOLM, SWEDEN (UroToday.com) - In the ALSYMPCA trial, patients were randomized 2:1 to 6 injections of Ra-223 (50 kBq/kg IV every 4 wk) or matching placebo.

STOCKHOLM, SWEDEN (UroToday.com) - Neoadjuvant chemotherapy (NAC) offers a survival benefit to patients with muscle-invasive bladder cancer (MIBC).

STOCKHOLM, SWEDEN (UroToday.com) - Presented by D Petrylak,¹ D Smith,² L Appleman,³ M Fleming,⁴ A Hussain,⁵ R Dreicer,⁶ AO Sartor,⁷ N Shore,⁸ NJ Vogelzang,⁹ H Youssoufian,¹⁰ VA DiPippo,¹⁰ N Stambler,¹⁰ K Huang,¹⁰ RJ Israel¹⁰ at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

STOCKHOLM, SWEDEN (UroToday.com) - Testis cancer is the most common cancer in men aged 15-40 years, and the incidence is increasing.